Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.9700
+0.01111.16%
Volume:796.70K
Turnover:769.20K
Market Cap:4.09M
PE:-0.05
High:1.02
Open:0.9426
Low:0.9251
Close:0.9589
52wk High:20.33
52wk Low:0.6141
Shares:4.22M
Float Shares:4.11M
Volume Ratio:0.03
T/O Rate:19.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-19.8182
EPS(LYR):-30.8884
ROE:-3138.91%
ROA:-95.42%
PB:-0.67
PE(LYR):-0.03

Loading ...

Oberon AIM VCT Launches £1.85 Million Share Offer and Agrees Related Party Promotion Deal

TIPRANKS
·
Yesterday

ImmuPharma Raises £6.47m as Retail Offer Completes Ahead of AIM Share Admission

TIPRANKS
·
Yesterday

Craneware Buys Back 217,464 Shares for Treasury on AIM

TIPRANKS
·
Yesterday

What's Going On With AIM ImmunoTech Stock Friday?

Benzinga_recent_news
·
Mar 20

Young & Co.’s Brewery Director Increases Shareholding with AIM Purchase

TIPRANKS
·
Mar 20

Octopus AIM VCT 2 Cuts Share Count After Buyback, Updates Voting Rights

TIPRANKS
·
Mar 20

Hargreave Hale AIM VCT Cuts Share Count with New Buyback

TIPRANKS
·
Mar 19

Amex Halt Add Info Lst 1.250000

THOMSON REUTERS
·
Mar 18

Octopus AIM VCTs Publish Supplementary Prospectus for Ongoing Fundraising

TIPRANKS
·
Mar 18

Why Is AIM ImmunoTech Stock (AIM) Up Today?

TIPRANKS
·
Mar 18

Amex Halt Add Info Lst 1.230000

THOMSON REUTERS
·
Mar 18

AIM ImmunoTech Shares More Than Double After Japan Grants Patent for Experimental Cancer Drug

THOMSON REUTERS
·
Mar 18

Amex Halt Add Info Lst 1.550000

THOMSON REUTERS
·
Mar 18

AIM ImmunoTech Shares Surge 88% to $1.34 Premarket After Japan Grants Patent for Experimental Cancer Drug

THOMSON REUTERS
·
Mar 18

AIM announces approval of patent for Ampligen in Japan

TIPRANKS
·
Mar 18

AIM ImmunoTech wins final Japan patent approval for Ampligen-checkpoint inhibitor cancer therapy

Reuters
·
Mar 18

AIM ImmunoTech Inc - Japan Patent Expires December 20, 2039

THOMSON REUTERS
·
Mar 18

AIM ImmunoTech Inc - to Pursue Orphan Drug Designation in Japan for Ampligen in Pancreatic Cancer

THOMSON REUTERS
·
Mar 18

AIM Vaccine Sets March 30 Board Meeting to Approve 2025 Results and Consider Dividend

TIPRANKS
·
Mar 18

Character Group Cancels Shares After Latest Buyback on AIM

TIPRANKS
·
Mar 18